INTRODUCTION
Current chemotherapy treatments define rates of cancer patient survival that have remained largely unchanged over the past 3 decades (Jemal et al., 2010) . This implies that alternative conceptual and practical approaches are required to treat human cancer. Increasing evidence suggests that cancer/tumor development is due to a rare population of cells, termed cancer stem cells (CSCs) (Dick, 2009; Reya et al., 2001 ) that uniquely initiates and sustains disease. In addition, experimental evidence indicates that conventional chemotherapeutics are actually ineffective against human CSCs (Guan et al., 2003) . This resistance to chemotherapeutics in the human is coupled with indiscriminate cytotoxicity that often affects healthy stem and progenitor cells, leading to dose restriction and necessitating supportive treatment (Smith et al., 2006) . Recent examples include selective induction of apoptosis (Atkinson et al., 2011; Gupta et al., 2009 ) that remains to be tested in normal SCs or in the human system, or driven by a specific oncogenic factor. Accordingly, assays for human CSCs and normal SCs that allow identification of agents that target CSCs alone are now critical to provide truly selective anticancer drugs that could be useful for preclinical testing.
Normal and neoplastic SCs are functionally defined by a tightly controlled equilibrium between self-renewal versus differentiation potential. In the case of CSCs, this equilibrium shifts toward enhanced self-renewal and survival leading to limited differentiation capacity allowing tumor growth. In contrast to direct toxic effects that equally affect normal SCs, an alternative approach, eradication of CSCs, may be achievable by overcoming the differentiation block of CSCs. First proposed in the 1970s (Sachs, 1978) , this approach led to the identification and clinical use of all-trans-retinoic acid (ATRA) (Breitman et al., 1980) and arsenic trioxide (ATO) (Niu et al., 1999) for patients with acute promyelocytic leukemias (APLs). Subsequent studies have demonstrated that both of these agents exert their effects by targeting the PML-RARa oncogenic fusion protein that is specific to APL (Yoshida et al., 1996) . In contrast to the human, murine studies indicate degradation of PML-RARa leads to APL remission, whereas ATRA's differentiation-inducing properties may be secondary (Nasr et al., 2008) . Despite these murine observations, combined ATRA and ATO therapy allows for > 93% remission rates with a 5 year overall patient survival rate approaching 100% (Wang and Chen, 2008) , exemplifying how understanding differentiation induction can be used in cancer.
Cancer differentiation therapy has not been translated to the treatment of other cancers, let alone other acute myeloid leukemia (AML) subtypes (Estey et al., 1999) . This may be in part due to the absence of robust in vitro assays that can interrogate human CSC differentiation. To this end, we have previously described a variant human pluripotent stem cell (hPSC) line that faithfully reproduces, in vitro and in vivo, neoplastic properties of somatic CSCs, including enhanced self-renewal and survival and aberrant block in differentiation capacity (Werbowetski-Ogilvie et al., 2009) . Based on these shared properties with somatic CSCs, we examined whether neoplastic hPSCs could serve as a surrogate for somatic CSCs that would be amenable for high content screening in vitro.
RESULTS

Differentiation Response of Neoplastic hPSC Models of Human Cancer
The inability of neoplastic hPSCs to terminally differentiate while retaining self-renewing capacity represents key in vivo features used to functionally define somatic CSC development in human tumors (Werbowetski-Ogilvie et al., 2009) . Distinct from pluripotent teratomas generated from normal hPSCs, teratomas generated from neoplastic hPSCs show features of more primitive lineage-specific cells and retain a primitive Oct4+ population (Figures 1A and 1B) (Werbowetski-Ogilvie et al., 2009 See also Figure S1 and Tables S1 and S2. secondary teratoma generation capacity (Table S1 ), demonstrating unique self-renewal capacity versus normal hPSCs despite being subjected to the strong in vivo differentiationinducing environment. In vivo similarities of neoplastic hPSCs to functional features of somatic CSCs (Reya et al., 2001) , coupled with the feasibility of culturing hPSCs, formed the basis to examine whether neoplastic hPSCs and their normal hPSC counterparts could serve as a surrogate-model system to identify and validate selective anti-CSC agents based on differentiation induction. Differentiation of human SCs occurs only by initial attenuation of regulators that maintain a self-renewing state. In the case of hPSCs, suppression of differentiation is governed by master pluripotency transcription factors of which Octamer 4 (Oct4) and SRY-box 2 (Sox2) (Boyer et al., 2005) are central. Loss of Oct4 is one of the first identifiable steps of commitment from pluripotent state toward differentiation (Nichols et al., 1998) . Bone Morphogenetic Protein 4 (BMP4) induces differentiation of hPSCs (Chadwick et al., 2003; Desbordes et al., 2008; Xu et al., 2002) , resulting in immediate reduction of Oct4 in normal ( Figure 1C ) and neoplastic ( Figure 1D and Figure S1A available online) hPSCs. Similarly, BMP4 treatment reduced Sox2 in normal ( Figure S1B ) and neoplastic (Figures S1C and S1D) hPSCs, confirming loss of the pluripotent state. BMP4-induced loss of pluripotency concomitantly resulted in downregulation of a network of genes associated with pluripotency, and upregulation of > 20 genes associated with differentiation programming ( Figure S1E ) in both normal ( Figure S1F ) and neoplastic (Figure S1G) hPSCs relative to treated controls (Figures S1H and S1I). These data indicate that reduction of Oct4 and Sox2 in viable cells provides a reliable indicator of loss of the self-renewing pluripotent state accompanied by differentiation induction of normal and neoplastic hPSCs.
To provide a straightforward method for detecting loss of Oct4 or Sox2, we generated green fluorescent protein (GFP) reporter lines by transduction of neoplastic hPSCs with the EOS-GFP reporter (v1H9-Oct4-GFP and v1H9-Sox2-GFP, respectively) (Hotta et al., 2009) . GFP intensity correlated with Oct4 and Sox2 expression in treatments that favored self-renewal stability and conditions that induced differentiation with the addition of BMP4 ( Figure 1D and Figure S1D ). This response was consistently found by using an additional neoplastic hPSC line, v2H9 (Werbowetski-Ogilvie et al., 2009 ) transduced with the same EOS-lentivirus GFP reporter (v2H9-Oct4-GFP; Figure S1J ), as well as a Sox2 reporter line (v1H9-Sox2-GFP; Figure S1D ). The uniform response to differentiation and maintenance of pluripotency in all hPSC lines generated also reveals that viral integration or clonal selection by EOS reporter construct insertion is irrelevant to responsiveness.
These results suggest that compounds that induce differentiation can be identified based on the reduction of GFP intensity in neoplastic hPSC reporter lines and could be exploited for chemical screening. To that end, conditions for automated high content microscopy (HCS) and fluorimetric-based highthroughput plate reader screening (PRS) were used to detect reductions in pluripotency marker expression of hPSCs. Microscopic analysis of normal hPSCs showed that distinct Oct4+ cells are lost after BMP4 treatment ( Figures S1K and S1L) . Similarly, the reduction in both GFP and Oct4 due to BMP4 treatment of neoplastic Oct4-GFP hPSCs was quantified by HCS ( Figures  S1M and S1N ) and PRS ( Figures S1O and S1P ). BMP4-treated (+BMP4) versus standard culture conditions (ÀBMP4) were demarked ''differentiated-state'' and ''pluripotent-state'' thresholds, respectively ( Figures 1C, 1D ,and 1K-1N), and used for evaluation of chemical libraries containing compounds of unknown function on human SCs. These data provide the parameters for a screening platform employing both normal and neoplastic hPSCs to identify anticancer agents that represent inducers of neoplastic cell differentiation.
Both HCS and PRS assays were optimized for 96-well plate screening (Figures S1Q-S1V, see Extended Experimental Procedures for optimization and definition of this hPSC culture platform). This hPSC-screening platform was validated by using an assembled library of 51 defined compounds with established stem cell and anticancer activity ( Figure 1E and Table S2 ).
The level of pluripotency marker expression and cell count (defined by nuclei stained with Hoechst) for each compound were recorded by using automated microscopy. Comparison of normal versus neoplastic hPSC cell counts revealed 12 compounds cytotoxic to normal hPSCs of which 11 were also cytotoxic to neoplastic hPSCs ( Figure 1F ). Such nonselective cytotoxic compounds that equally target normal SCs are of limited value and were excluded from further evaluation. Instead, preferred compounds were selected for the ability to reduce Oct4 by selectively inducing differentiation of neoplastic hPSCs, whereas having little effect on normal hPSCs. To identify such an ideal candidate compound that fulfills the above criterion, differentiation of both normal and neoplastic hPSCs in response to compound treatment was assessed in parallel (Figure 1G) . Using these 51 compounds, three distinct regions of response could be resolved based on cellular response: (1) no discernable reduction in pluripotency for differentiation (38 compounds); (2) differentiation of normal hPSCs alone (nine compounds); and (3) differentiation induction of both normal and neoplastic hPSCs (four compounds) ( Figures 1G and 1H) . Importantly, active compounds from regions B and C were not detectable by using conventional cell lines utilized in drug screening, e.g., HeLa cells ( Figures S1W-S1Z ), illustrating the read-out in this hPSC-based platform.
Compounds that can induce differentiation of neoplastic hPSCs are potential anticancer candidates. Region C maps four such compounds; salinomycin, rapamycin, indolactam, and PMA. These compounds also differentiate normal hPSCs ( Figure 1G ) and are useful in verifying, defining, and validating our screen. However, inducers of normal SC differentiation were deemed undesirable as anti-CSC agents due to the likely exhaustion of the normal SC population through overstimulation of differentiation. Instead, the ideal compound should only differentiate neoplastic hPSCs while not affecting normal hPSCs.
Identification of Compounds that Induce Differentiation of Neoplastic hPSCs
Given the validation of our screening platform (Figure 1 ), we extended our tests to chemical libraries composed of 590 wellestablished annotated compounds from the NIH Clinical Collection and Canadian Compound Collection (Table S3 ). PRS and HCS platforms give equivalent measurements (Figures S1Y-S1Z). PRS was selected for more rapidly screening compound libraries ( Figure 2A ). Of the 590 compounds screened (at 10 mM based on previous studies), 11 compounds were identified to induce differentiation as indicated by a reduction in both GFP percentage residual activity (%RA) and Hoechst %RA ( Figures 2B and 2C ). Four of these compounds (indatraline, thioridazine, azathioprine, and mefloquine) were identified as candidate compounds based on clustering and levels of Hoechst %RA in excess of 30% ( Figure 2B ). Secondary high content analysis did not validate indatraline as a candidate and was thus excluded, whereas high content and PRS analyses dually confirmed thioridazine, azathioprine, and mefloquine as candidate compounds ( Figure 2D ) and were thus selected for further testing ( Figures 2E-2G ). When compared to controltreated hPSCs (Figures 2E and 2F) , each compound appeared to induce distinct morphological changes in neoplastic hPSCs ( Figure 2E ). Reduction in GFP intensity was confirmed by using image analysis ( Figure 2F ) and further assessed over a wide range of doses to calculate the half-maximal effective concentration (EC 50 ) for each compound (Figures 2G and Figure S2 ). Only thioridazine and mefloquine were found to possess EC 50 values lower than the 10 mM target threshold ( Figure 2G ) and thus defined as candidates for further in-depth evaluation by using neoplastic hPSCs and somatic CSCs from patients.
Thioridazine Selectively Induces Neoplastic hPSC Differentiation and Reduces AML-Blasts without Affecting Normal HSPCs
The responses to thioridazine and mefloquine were evaluated in both normal ( Figure 3A ) and neoplastic hPSCs ( Figure 3B ) at three concentrations by using quantitative flow cytometry to detect the loss of Oct4 and reveal the degree of differentiation. Salinomycin, a reported selective inhibitor of breast CSCs (Gupta et al., 2009) , was included for comparison. At 10 mM, all compounds reduced the number of cells, but the levels of Oct4 in remaining normal hPSCs were not below levels observed with BMP4 treatment ( Figure 3A ). This same response was replicated in fibroblast-derived human iPSCs ( Figure S3A ), representing an additional normal hPSC line from a distinct (adult) origin, indicating the effects are not specific to embryonic sources. When the same compounds were used to treat neoplastic hPSCs, mefloquine and thioridazine treatments caused reductions in cell number and levels of Oct4. Only thioridazine was able to reduce levels of Oct4 below BMP4 differentiation controls ( Figure 3B and Figure S3B ), indicating the ability of thioridazine to overcome the neoplastic hPSC differentiation block. To identify compounds that selectively differentiate neoplastic hPSCs quantitatively, the ratio of normalized percentage of Oct4+ cells between normal and neoplastic hPSCs in response to these compounds was determined. For example, a ratio of 1 suggests equivalent differentiation whereas a ratio > 1 defines relatively more differentiation in neoplastic hPSCs versus normal hPSCs. Only thioridazine, at both 1 mM and 10 mM, had a significant impact on inducing differentiation of neoplastic hPSCs over normal hPSCs ( Figure 3C ). Rapid accumulation of the cell stress marker p53 ( Figure 3D ) and its transcriptional target p21 (Figure 3E) were used to further distinguish differentiation induction from cellular toxicity. Treatment of neoplastic hPSCs with the toxic chemotherapeutic agent etoposide resulted in high levels of p53 and p21 after 24 hr. However, treatment with 10 mM thioridazine or BMP4, unlike agents that induce toxicity alone, resulted in no accumulation of p53 or p21, consistent with induced differentiation rather than stress-response programs. Furthermore, thioridazine treatment led to expression of differentiation genes quantified by TaqMan Low-Density Array-qPCR in neoplastic hPSCs. An upregulation in 21 of 50 differentiationassociated genes ( Figure 3F ) was observed in treated neoplastic hPSCs consistent with the differentiation-inducing effects of thioridazine.
To examine the potential similarities in chemical response of neoplastic hPSCs to somatic CSCs, we assessed normal and neoplastic populations of the human hematopoietic system by using powerful and well established in vitro and in vivo assays (Bhatia et al., 1997; Bonnet and Dick, 1997) . Lineage-depleted umbilical cord blood (CB linÀ) is highly enriched for hematopoietic stem-progenitor cells (HSPCs) and is a reliable source of normal somatic SCs capable of self-renewal and multi-lineage differentiation to all blood lineages. AML is a hematological neoplasia characterized by a block in mature myeloid differentiation that is sustained by a self-renewing leukemic stem cell (LSC) (Lapidot et al., 1994) . As such, progenitor assays in methylcellulose were conducted with HSPCs and five AML patient samples, each treated with thioridazine, mefloquine, or salinomycin in order to assess each compound's impact on in vitro clonogenic and multilineage hematopoietic differentiation. Representative cell pellets of the total colony-forming units (CFUs) generated from HSPCs ( Figure 3G ) and AML ( Figure 3H ) treated with each compound are shown. Thioridazine treatment resulted in a reduction in AML proliferation/clonogenic capacity while retaining HSPC multilineage differentiation ( Figure S3C ). Changes in multilineage differentiation were quantified based on the enumeration of CFUs generated following treatment of HSPCs ( Figure 3I ) and AML patient ( Figure 3J ) samples with these compounds. At both 1 mM and 10 mM salinomycin reduced AML-blast CFU potential ( Figure 3J ) but also reduced HSPC CFU potential over all doses tested ( Figure 3I ), indicative of nonspecific toxicity in the hematopoietic system. In contrast, mefloquine and thioridazine reduced AML-blast CFU formation ( Figure 3J ) while having little effect on HSPC CFU potential (Figure 3I ) and multilineage composition ( Figure S3D ), indicating that mefloquine and thioridazine do not alter normal hematopoiesis.
We calculated the ratio between total CFUs generated from HSPCs versus AML-blasts to reveal the highest selectivity for targeting AML ( Figure 3K ). A ratio of 1 suggests equivalent normal to neoplastic progenitor potential whereas a ratio > 1 defines a compound that selectively reduces AML-blast CFU potential. Salinomycin (1 mM), mefloquine (10 mM), and thioridazine (10 mM) doses yielded the highest ratio values for each compound ( Figure 3K ) and were thus selected for in vivo evaluation. Thioridazine 10 mM, in particular, demonstrated the highest ratio of all compounds but most importantly was the only compound to show significantly lower AML-blast CFU potential relative to normal HSPC CFU potential ( Figure 3K ). To address whether thioridazine's specificity was due to induction of differentiation, the frequency of CD11b, a marker of granulocytic (G) Dose-response curves of v1H9-Oct4-GFP treated with candidate compounds and calculation of EC 50 . Each point n = 3; mean ± SEM. See also Figure S2 and Table S3 . maturation in patient AML cells, was assayed in response to thioridazine treatment ( Figure 3L) . A marked increase in the frequency of granulocytic AML-blast cells was observed with treatment duration (Figure 3L ), indicating that thioridazine exhibits its specific targeting of AML cells through induction of differentiation. This finding is analogous to differentiation-induction demonstrated in neoplastic hPSCs (Figures 3A-3F ) and confirms the robust readout of this screening platform toward identifying agents able to differentiate neoplastic cells. This result also suggests that thioridazine may represent the best candidate for specific targeting of AML CSCs, which requires testing using in vivo human-mouse xenograft assays.
Identification of Antileukemic Agents by Using Neoplastic hPSC Screening
To reaffirm our screening approach and specificity to identify thioridazine-like compounds, we expanded the chemical matter used to screen neoplastic hPSC response to include 2,446 compounds ( Figure 4A ). Thioridazine, along with two other phenothiazine compounds, fluphenazine and prochlorperazine, were identified as hits among a list of 26 compounds identified ( Figures 4A-4C) . Similarly, rapamycin, an mTOR-inhibitor, and lestaurtinib, a tyrosine kinase inhibitor, were both independently identified and are previously known to have antileukemic properties ( Figures 4A-4C ). Rapamycin's antileukemic effects have been studied in mouse models (Yilmaz et al., 2006) and demonstrated in human AML patients (Ré cher et al., 2005) . Lestaurtinib's antileukemic properties have been associated with differentiation-induction (Zheng et al., 2002) and also tested in human AML patients (Smith et al., 2004) . Further assessment of fluphenazine, prochlorperazine, rapamycin, and lestaurtinib by using high content analysis revealed distinct morphological changes in neoplastic hPSCs ( Figure 4D ) relative to controltreated cells ( Figure S4A ). Reduction in GFP intensity was confirmed by using image analysis ( Figure 4E ) and further assessed over a wide range of doses to calculate the EC 50 for each compound ( Figure 4F ). Of the three phenothiazines identified in the screens, thioridazine (confirmed by chemical analyses Figures S4B-S4H ) exhibited the lowest EC 50 in neoplastic hPSCs ( Figure 2G versus Figure 4F ), making it the best candidate phenothiazine of those tested for targeting of AML CSCs by using human-mouse xenograft assays as in vivo readouts. The identification of rapamycin and lestaurtinib, two established clinically-relevant antileukemic agents, reinforces the detection capacity of our screen by using the neoplastic hPSC assays designed in our study.
Thioridazine Reduces LSC Function while Sparing Normal Human Repopulating Cells
To delineate whether the inhibition of AML-blasts detected in vitro was due to the compounds affecting the neoplastic stem cell compartment, xenotransplantation studies (Dick, 2008) that functionally define LSCs and hematopoietic stem cells (HSCs) were conducted ( Figures 5A-5E ). Treatment of HSPCs with salinomycin (1 mM) significantly reduced hematopoietic engraftment to almost nondetectable levels ( Figure S5A ) revealing that this compound interferes with normal hematopoiesis from HSPCs and was thus excluded from further evaluation as it is unlikely to provide the selective anti-CSC therapeutic targeting desired. In contrast, mefloquine (10 mM) treatment displayed a slight, yet insignificant, reduction in HSC capacity relative to controls ( Figure 5A ). However, mefloquine proved ineffective in reducing AML LSC capacity and was thus discontinued from further evaluation due to absence of selective effects ( Figure 5C ).
In contrast to both salinomycin and mefloquine, treatment of HSPCs with thioridazine (10 mM) displayed the same level of bone marrow (BM) engraftment ( Figure 5A ) and splenic engraftment ( Figure S5B ) as control vehicle-treated cells. Multilineage reconstitution capacity was identical between control-and thioridazine-treated human HSCs with myeloid ( Figure 5B ), lymphoid ( Figure 5B ), erythroid ( Figure S5D ), and megakaryocytic development ( Figure S5D ) completely unaffected. As measured by secondary serial transplantation, thioridazine treatment did not affect HSC self-renewal as compared to self-renewal in control-treated samples ( Figure S5F ). Thioridazine treatment was able to significantly reduce leukemic disease-initiating AML LSCs (Figures 5C and5D and Figures S5C and S5E ). Calculating the ratio of HSPC normal hematopoietic regeneration (%hCD45+) to AML leukemogenesis (%CD33+hCD45+ blasts) revealed that thioridazine significantly reduced LSC function while preserving normal HSC capacity ( Figure 5E ). In the absence of thioridazine, no difference in the level of leukemic engraftment of secondary transplant recipients was observed ( Figure S5G ). This suggests that continued exposure to this drug is necessary to inhibit leukemogenesis in secondary recipients. These data demonstrate that thioridazine selectively targets somatic CSCs while having no effect on normal SC properties in vivo.
Dopamine Receptor Expression Provides a Potential Target of Human CSCs
Thioridazine is known to act through the dopamine receptors (DR1-5) (Seeman and Lee, 1975) . To assess whether the mechanism of thioridazine action to selectively interfere with human CSCs versus normal SCs is via DR antagonism, we analyzed DR cell-surface expression. To date, five DRs have been identified and divided into D1-family (D1 and D5) and D2-family (D2, D3, and D4) receptors (Sibley and Monsma, 1992) . Normal hPSCs expressing the pluripotent marker SSEA3 were devoid of DR expression ( Figure 6A and Figures S6A and S6B ). In contrast, neoplastic hPSCs expressed all five DRs ( Figure 6B ). The observed differential expression of DRs and the selective inhibition of thioridazine for neoplastic hPSCs suggest that inhibition of DR signaling may play a role in selective targeting of human CSCs versus normal SCs.
To expand the potential role of DRs in CSCs based on the functional role of thioridazine treatment, we examined whether DR antagonism could account for the loss of LSC function following thioridazine treatment. Expression of DR1-5 was analyzed in HSPCs ( Figure 6C ) and human hematopoietic mononuclear cells from normal CB (Figures S6C-S6F ) and AML patient samples ( Figure 6D and Figure S6G ). DRs were not observed in the primitive HSCs or progenitor populations of CB (identified as the CD34+38À or CD34+38+ fractions, respectively [Bhatia et al., 1997] DRs were undetectable on the surfaces of erythroid ( Figure S6C ), megakaryocytic ( Figure S6C ), and lymphoid cells ( Figure S6D ). Only monocytes defined as CD14+ and approximately half the population of granulocytes defined as CD15+ expressed DRs ( Figures S6E and S6F) . All of the 13 AML patient samples analyzed contained a population of DR+ blasts with varying levels of all five receptors ( Figure 6D ) and were predominately detected in CD34+/CD14+ cells ( Figure S6G ). However, unlike normal HSCs, CD34+ cells do not correlate with LSC capacity in human AML (Taussig et al., 2008) . Recently, LSCs have been identified in numerous subfractions devoid of CD34 or CD38 (Eppert et al., 2011 Figure S6H ). This finding is consistent with the low levels of DRs found in normal mammary gland tissue, whereas benign breast tumors show intermediate levels and breast cancers display high levels of these receptors (Carlo et al., 1986) . Our observations of differential DR expression between normal and neoplastic patient samples strongly suggest human CSCs are heterogeneous and drug targeting should be based on molecular pathways instead of surrogate phenotypic markers. We investigated whether the DR expression in AML-blasts was correlative to incidence of LSCs in AML patients. AML samples with a large fraction of DRD3+ blasts ( Figure 6G ) and DRD5+ blasts ( Figure 6H ) contain LSCs as they are able to initiate leukemia in xenotransplantation recipients, unlike AML patient samples with significantly lower levels of DRs that do not contain LSCs. Samples from AML patients containing LSCs have been correlated to poor prognostic outcome while non-LSC samples demonstrate a good prognosis (Eppert et al., 2011) . High levels of DR expression correlate with poor prognosis, whereas low levels demonstrate good prognosis ( Figures 6G and 6H) suggesting that DR assessment has prognostic biomarker applications and is less complicated than complex molecular signatures or LSC readouts in mice for each AML patient.
Thioridazine Inhibits Human AML and Augments Effects of AraC
To better understand the functional role of DRs in human AML, two AML cell lines (AML-OCI2 and AML-OCI3) derived from patients that express each DR1-5 ( Figure 7A ) at elevated levels were utilized. Both AML lines were treated with thioridazine and compared to other known DR antagonists, clozapine and chlorpromazine (Seeman and Lee, 1975) . All three reduced the number of AML cells upon treatment ( Figure 7B ). To further evaluate the specificity of DR targeting on human AML cells, patient AML samples were divided into DR+ and DRÀ subfractions by using fluorescence-activated cell sorting before being treated with a DMSO vehicle or thioridazine for 24 hr and then assayed for blast-CFU content. A reduction in blast-CFU generation was only observed in the DR+ subfraction treated with thioridazine ( Figure S7A ), whereas no reduction was observed in the DRÀ subfraction treated with thioridazine ( Figure S7B) . Conversely, the addition of a DR D2-family agonist, 7OH-DPAT, increased the number of AML cells ( Figure 7C ). DR D2-family and D1-family exert opposing actions on intracellular signaling, leading to differential biological effects (Self et al., 1996) . Treatment with a DR D1-family agonist, SKF38393, resulted in a significant reduction in AML cell number, confirming that D2-family signaling is necessary for AML cell survival (Figure 7D ). These combined results suggest the mechanism of thioridazine's action is through antagonism of D2-family DRs and not due to off-target effects, and identifies an alternative avenue of CSC targeting via DR signaling. Although thioridazine is able to bind to DR2 receptors at low nanomolar concentrations (Seeman and Ulpian, 1983), we show that at least 10 mM is required to generate an anti-CSC effect. This dose is within the clinically-tolerable range required to induce antipsychotic effects in patients ( Figure S7C ). However, this relatively high concentration suggests that thioridazine may activate other undefined targets that may work in synergy or independently of DR signaling for overall anti-CSC impact.
Upon establishing thioridazine's anti-LSC effect at clinicallytolerable doses ( Figure S7C ), we investigated whether this drug could be combined with conventional AML chemotherapy using cytarabine (AraC). Although AraC is the standard chemotherapeutic used in both induction and consolidation therapy of adult human AML, this treatment poses significant morbidity and mortality risks at high doses (Estey and Dö hner, 2006) . Using normal HSPC versus AML-blast detection, at concentrations R 1 mM, AraC induced complete toxicity of AML CFU blasts; however, it was equally sufficient at eliminating normal HSPCs ( Figure 7E ). Using various doses we identified AraC's effective concentration (EC AraC ), as defined by the concentration that reduced AML-blast-CFU while retaining HSPC function, to be at 100 nM ( Figure 7E) . However, the combination of thioridazine at 10 mM with AraC reduced the effective concentration (EC AraC+Thio ) to 1 nM ( Figure 7F ) representing a 100-fold reduc- tion in the AraC dosage required. Alternatively, the combination of thioridazine at 10 mM with AraC at 100 nM demonstrates almost complete elimination of AMLblast-CFUs while preserving HSPC function ( Figure 7F ), suggesting that these specified concentrations can induce remission and prevent relapse of AML in patients. Collectively, these data show the synergistic benefit of combining an anti-LSC agent (thioridazine) with an antiproliferative agent (AraC) currently used as a single first-line treatment for human AML and to targeting CSCs in addition to other cells in the leukemogenic hierarchy. This combined effect with thioridazine is likely to have significant benefit to AML patients as it can reduce the severe cytotoxic effects associated with highdose AraC therapy, as illustrated in Figure S7D .
DISCUSSION
Unlike other assays that are limited to using CSCs alone, murine systems, cancer cell lines, or cancer initiation driven by overexpression of a unique oncogene, our platform has the capacity to compare each candidate compound with normal SC and CSC counterparts to capture compounds that selectively target CSCs in the human. Based on our study, we propose the following model to depict the role of differentiation-inducing drugs as anti-CSC therapeutics ( Figure 7G ). Differentiation-inducers capable of uniquely acting on CSCs may be capable of antagonizing unusual pathways usurped for survival of CSCs and tumor generation that are not expressed by normal SCs in the same tissue. By identifying and inhibiting these pathways, CSCs can be made responsive to differentiation and produce differentiated progeny that enter into normal cellular life cycles ( Figure 7G ). By example, Thioridazine, an FDA-approved antipsychotic DR antagonist of the phenothiazine group, represents one such candidate compound and pathway that was revealed by using our human CSC-screening platform.
The identification of thioridazine and its ability to selectively target LSCs suggest that neoplastic hPSCs can provide a reliable in vitro surrogate to model somatic human CSCs. Our results and approach are consistent with the idea that gene expression analyses of poorly differentiated human tumors display an embryonic stem cell-like signature that correlates with poor clinical outcome (Ben-Porath et al., 2008) . Complementary to this notion, neoplastic hPSCs may possess pathways shared with all somatic CSCs and/or harbor unique lineage-specific CSC pathways based on their pluripotent nature. Our experimental findings support these concepts and provide experimental support for an in vitro CSC differentiation model that uses hPSCs and is also amendable to automated drug-screening methodologies and mechanistic studies. For example, by representing a selective inducer of CSC differentiation, we show that thioridazine exerts its anti-CSC activity via antagonism of D2-family DRs differentially expressed on neoplastic SCs. Equally important, we show that thioridazine does not affect normal human somatic stem cells-thus satisfying an unmet need for identification of selective anti-CSC agents that can be used at escalating doses in the clinic. DR signaling therefore represents a drugable receptor pathway yet to be described in the context of human CSCs and is, to the best of our knowledge, the only drugable receptor pathway specific to CSCs in the human. The anticancer effects of thioridazine and other phenothiazines have been reported in lymphoblastic leukemia cell lines although they are less toxic to normal lymphocytes (Zhelev et al., 2004) . This selective response was attributed to inhibition of mitochondrial DNA polymerase and decreased ATP production. Although mitochondrial DNA polymerase was present for lymphoblastic leukemic cell lines, there was no evidence that mitochondrial DNA polymerase was inactive in normal lymphocytes, casting doubt as to whether thioridazine's effects are due to this mechanism and limited to the lymphoid system. Here, we suggest and demonstrate an alternative mechanism by using primary human patient AML cells versus normal HSPCs, which indicates that the selective expression of DRs on neoplastic stem cells can be targeted by using DR antagonists.
Several DR antagonists are already in clinical use. Interestingly, schizophrenic patients receiving DR antagonist medication at doses deemed effective for schizophrenia were reported to have a reduced incidence of rectum, colon, and prostate cancer compared to the general population (Dalton et al., A total of eight AML patient samples were assessed for leukemic-initiation potential in xenotransplantation recipients. Leukemic-initiating was defined as human engraftment > 0.1% of CD33+ hCD45+ in mouse bone marrow. Four leukemic-initiating AML samples were assayed in 22 mice, whereas four noninitiating AML samples were assayed in 17 mice. Total n = 8 AML samples; mean ± SEM. See also Figure S6 .
2005); this suggests that development of some cancers may be DR-dependent. These findings are further corroborated by the lower cancer incidence rates observed in dopaminergicdeficient Parkinson's patients (Driver et al., 2007) as Parkinson's disease itself can be considered to be functionally akin to disease-induced DR antagonism. It is conceivable that non-CSC populations within the tumor may be resistant to anti-CSC agents, and their elimination must be taken into consideration when formulating drug treatments. Based on our findings, further investigation is required to elucidate whether DR upregulation is a more generalizable biomarker of tissue-specific CSCs (outside of brain tumors), and what survival benefit is derived from expressing these receptors. We believe an understanding of the prominence of DR signaling in human cancer and cancer progression would permit development of targeted anti-CSC therapies.
EXPERIMENTAL PROCEDURES
Generation of Neoplastic hPSC EOS-GFP Lines
Neoplastic v1H9 or v2H9 hPSC cells (Werbowetski-Ogilvie et al., 2009) were transduced with lentivirus bearing the EOS-C3+ or EOS-S4+ vectors provided by Dr. James Ellis (Hotta et al., 2009) . After lentiviral transduction cells were selected by using Puromycin and subsequently sorted as single cells into a 96-well plate based on GFP expression by using a FASCAria II (Becton Dickinson). Colonies generated from single cell clones were used to establish the v1H9-Oct4-GFP (EOS-C3+), v2H9-Oct4-GFP (EOS-C3+) and v1H9-Sox2-GFP (EOS-S4+) lines.
Cell Culture
The H9 hESC, v1H9, v1H9-Oct4-GFP, v2H9-Oct4-GFP, v1H9-Sox2-GFP, and fibroblast-derived iPSCs were cultured as previously described (Chadwick et al., 2003; Werbowetski-Ogilvie et al., 2009 ).
Screening with Neoplastic and Normal hPSCs
Chemical screens involved v1H9-Oct4-GFP cells seeded at 5,000 cells per well in mouse embryonic fibroblast conditioned media (MEFCM) supplemented with 8 ng/ml bFGF. Twenty-four hours later the media was exchanged for MEFCM with compounds at 10 mM and 0.1% DMSO, 0.1% DMSO (ÀBMP4) or 100 ng/ml of BMP4 and 0.1% DMSO (+BMP4) for 48 hr then exchanged with fresh media with compound for a further 24 hr (total compound treatment time 72 hr) prior to being fixed and prepared for automated imaging and plate reader analysis. Confluent H9 and fibroblast-derived iPSC were seeded at 10,000 cells per well in MEFCM supplemented with 8 ng/ ml bFGF. Twenty-four hours later the cells were treated with the same compound formulation used for v1H9-Oct4-GFP. Fresh MEFCM supplemented with compounds was exchanged daily for 5 days. On day 5, hPSCs were fixed and prepared for automated imaging and plate reader analysis.
Images were acquired at 103 0.45 N.A with an Arrayscan HCS VTI Reader (Cellomics) by means of epifluorescence illumination and standard filter sets. See Extended Experimental Procedures for further details.
Image Analysis
Image analysis was performed by using custom scripts in Acapella software (Perkin Elmer). Nuclear objects were segmented from the Hoechst signal. For neoplastic cell lines, object intensity analysis was performed on GFP-positive cells only. For normal cell lines, the fraction of Alexa-Fluor-647-positive cells was quantified. Images and well-level data were stored and analyzed in a Columbus Database (Perkin Elmer) and further data analysis, compounds registration and hit identification in ActivityBase (IDBS).
Statistical Analysis
Data are represented as the mean ± SEM or mean ± SD. Significant differences between groups were determined via unpaired two-way or one-way Students' t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and three tables and can be found with this article online at doi:10.1016/j.cell.2012.03.049.
